Nutex Health (NUTX) Stock: Buy, Sell, or Hold?
NUTX - Nutex Health Inc. Common Stock
$200.24
5.04 (2.58%)
▲
5d:
+1.3%
30d:
+16.11%
90d:
+36.21%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When NUTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: NUTX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: NUTX shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$379.94
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$235.91
15.1% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 7.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: NUTX is currently trading at $200.24, which is considered extended relative to its 30-day fair value range of $171.69 to $198.19. The stock's valuation (Forward PE: 7.2) is in line with its historical norms (7.0). At these levels, the market is pricing in 0.9% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, NUTX is in a strong uptrend. The price is approaching resistance at $202.50. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: NUTX scores 32/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $283.00 (+41.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NUTX is in a strong uptrend. The price is approaching resistance at $202.50. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: NUTX scores 32/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $283.00 (+41.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$171.69 -
$198.19
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
29.5%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (32/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 41.3% below Wall St target ($283.00)
- NEUTRAL: Market pricing in 0.9% annual earnings growth - fairly valued
- WARNING: Composite score 45/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$171.69 -
$198.19
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$182.66
Resistance Level
$202.50
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
7.18
Wall Street Target
$283.00
(+41.3%)
Revenue Growth (YoY)
-13.6%
Earnings Growth (YoY)
95.9%
Profit Margin
21.2%
Valuation Premium vs History
+0.9% premium
PE vs Historical
7.2 vs 7.0
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.9%
(market-implied from PE analysis)
1-Year Target
$202.04
(+1%)
2-Year Target
$203.86
(+2%)
3-Year Target
$205.70
(+3%)
3-Yr Target (if PE normalizes)
(PE: 7→7)
PE COMPRESSION
$200.42
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.2, Growth: 28.1%)
$566.92
(+183%)
Base:
(SPY PE: 7.2, Growth: 28.1%)
$201.93
(+1%)
Bear:
(PE: 6.1, Growth: 28.1%)
$171.64
(-14%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (8x PE), but valuation improves significantly next year (7x PE) as earnings recover.
Trailing PE: 7.56 | Current EPS (TTM): $25.81
Bull Case
$231.88
(+16%)
Analyst growth 8.0%, PE expands to 8.3
Base Case
$210.80
(+5%)
Market implied 8.0%, PE stable at 7.6
Bear Case
$132.74
(-34%)
Severe decline -20.0%, PE contracts to 6.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: September 12, 2026 3:04 PM ET
Data refreshes hourly during market hours. Next update: 4:04 PM
Data refreshes hourly during market hours. Next update: 4:04 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NUTX showing a specific setup today?
Insider Activity (6 Months)
3
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Frank E Jaumot
BUY
150 shares
2026-03-20
Warren Hosseinion
BUY
252 shares
2026-03-19
Kelvin Spears
BUY
10 shares
2026-03-17
Top Rated Medical Care Facilities Stocks
Top-rated stocks in Medical Care Facilities by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
THC
Tenet Healthcare Corpora… |
STRONG BUY
22 analysts |
$285 | 61 BUY |
|
HCA
HCA Healthcare, Inc. |
BUY
25 analysts |
$451 | 50 HOLD |
|
EHC
Encompass Health Corp |
STRONG BUY
12 analysts |
$148 | 55 HOLD |
|
CMPS
Compass Pathways Plc |
STRONG BUY
11 analysts |
$24 | 52 HOLD |
|
ADUS
Addus HomeCare Corporati… |
STRONG BUY
11 analysts |
$135 | 56 HOLD |
